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Primary Immunodeficiency Diseases in Oman: Five Years’
Experience at Sultan Qaboos University Hospital
Salem Al-Tamemi, MD, FRCPC,1 Ibtisam Elnour, MBBS, FRCPCH,1 and David Dennison, MBBS, MD2
Background: Primary immunodeﬁciency diseases (PIDs) are con-
sidered rare but are generally assumed to be more common in Middle
Eastern countries. The prevalence and characteristics of PIDs are
unknown in Oman.
Methods: Sultan Qaboos University Hospital is the national referral
center for PID in Oman during the study period. Patients were
diagnosed and classiﬁed according to the clinical and laboratory
criteria of PID reported by the International Union of Immunological
Societies Primary Immunodeﬁciency Diseases Classiﬁcation Com-
mittee. A registry was created, and patient data were analyzed
between July 2005 and July 2010.
Results: Over a 5-year period, there were a total of 90 patients, with
an estimated prevalence of 4.5 cases per 100,000. The most common
form of immunodeﬁciency was phagocyte disorders (42%), mainly
chronic granulomatous disease, followed by predominantly antibody
disorders (18%), other well-deﬁned PID syndromes (13%), and
combined immunodeﬁciencies (12%). The median age of onset of
symptoms was 9 months. The median age of diagnosis was
24 months. Consanguinity was present in 81% of patients. The
most common infectious presentation was pneumonia (42%),
followed by deep abscess (27%) and BCGosis (12%). A total of
25% of patients required intravenous immunoglobulins treatment,
4% required gamma interferon therapy, and 11% underwent bone
marrow transplantation. Of all PID patients, 90% survived treatment,
whereas 10% did not.
Conclusions: The estimated minimum prevalence of PID in Oman is
4.5 cases per 100,000, with a predominance of phagocyte disorders.
Consanguinity is a signiﬁcant factor; pneumonia and deep abscesses
were the main infectious presentations. The overall survival rate was
90%. Strategies are needed to improve the care for PID patients and
to increase the awareness among parents and physicians.
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Primary immunodeﬁciency diseases (PIDs) are consideredrare. With increasing knowledge of basic immunology,
and advancements in technical abilities in molecular biology,
plus numerous genetics studies over the last 2 decades, many
underlying causes of these diseases have become known,
which has helped in ﬁrm diagnosis and the creation of certain
management plans.1 Because PIDs are rare and phenotypi-
cally variable, and many primary physicians are not familiar
with these disorders, many patients arrive at immunology
specialists too late for proper diagnosis and treatment; often
there are complications secondary to manifestations of the
disease, which are associated with a compromised quality
of life, increased morbidity, and mortality.2
To foster a better understanding of these disorders,
registries have been created in different centers around the
globe, where valuable information is being collected. To date,
more than 120 distinct genes have been identiﬁed, whose
abnormalities account for more than 150 different forms of
PID. The study of these diseases has provided essential
insight into the functioning of the immune system. The
complexity of the genetic, immunological, and clinical
features of PID have prompted the need for their classiﬁca-
tion, with the ultimate goal of facilitating diagnosis and
treatment.3
Most registries from Western countries have reported
a predominance of antibody production defects over other
forms of PID.4–7 Additionally, there are a few reports from
Arabian countries and the Middle East. A group from Tunisia
reported 152 patients with PID over a period of 8 years, with
a mortality of 24%.8 One center in eastern Saudi Arabia found
that over a period of 6 years, 31 patients were diagnosed with
humoral immunodeﬁciency.9 Kuwait reported 76 patients
with PID between 2004 and 2006, of which 98% presented
in childhood with 77% consanguinity.10 An Egyptian study
reported 64 patients with a higher prevalence of combined
immunodeﬁciency over other forms and 62% consanguinity
and a mortality of 23%.11 The Iranian Primary Immunodeﬁ-
ciency Registry reported 440 patients with PID seen over
a period of 20 years. There was a predominance of antibody
production and phagocytic defects over other PID as com-
pared with other registries, and only 3 patients with comple-
ment deﬁciencies were identiﬁed.12 In other Asian countries,
like Taiwan, over a 20-year period, 37 patients were diag-
nosed with PID. Antibody production defects and phagocytic
function defects predominated over other forms of PID, and
no patients were identiﬁed with complement deﬁciencies.13
Speciﬁc registries for certain kinds of PID have been
established in certain countries. In the United States, there are
registries for chronic granulomatous disease (CGD) and
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X-linked agammaglobulinemia that have provided important
information for physicians.14,15 The European Society of
Immunodeﬁciency Registry has recently answered speciﬁc
questions on the quality of life of patients receiving gamma
globulin therapy for common variable immunodeﬁciencies,
favoring the subcutaneous route over the intravenous route,
which has been debated recently among immunologists.16
Because PIDs are genetic disorders and mostly
inherited in an autosomal recessive form, they are expected
to be more prevalent in societies where consanguineous
marriage is prevalent. It is important to have registries of
PIDs from different countries to understand the magnitude of
the problem and illustrate any particular features that would
help in managing these patients and performing effective
counseling. This also would help in strategic planning for
health care policy makers. A registry of PID in Oman was
established by the Immunology Unit at Sultan Qaboos
University Hospital (SQUH), the national referral center for
primary immunodeﬁciency patients in Oman.
METHODS
Oman, located in the southeastern Arabian Peninsula,
has a population of about 2 million Omani nationals and is
divided into 9 governorates and regions. The majority of
people living in Oman are of Arab ancestry. The health
system in Oman is mainly public with primary and secondary
health care available in all governorates and regions. Tertiary
care is available in Muscat, the capital of Oman, with SQUH
being the second largest tertiary care hospital in Oman. It is
the referral center for patients who are suspected of having
PID. Patients from different regions of the country are
referred for consultation, investigation, and management,
including stem cell transplants.
A registry for patients who are diagnosed with PID was
established by the Immunology Unit at the Department of
Child Health. The aim of this registry is to determine the
prevalence and frequency of different PIDs in Oman, to
identify clinical presentation patterns, consanguinity rates,
treatment patterns, natural history, morbidity and mortality,
and to determine if, in general, there is any particular pattern
for this group of inherited disorders. This information will
improve physicians’ knowledge about PID in Oman and will
also help with early detection, ultimately improving quality of
life and survival rates. Allocation of resources and better,
more strategic decision making will also result.
Patients were diagnosed and classiﬁed according to
the clinical and laboratory criteria of PID as reported by
International Union of Immunological Societies (IUIS) Pri-
mary Immunodeﬁciency Diseases Classiﬁcation Committee.3
Data were entered in Microsoft Access Datasheet and in-
cluded patient demographic data, clinical presentation,
infectious presentation, family history of PID, presence of
consanguinity, previous death in the family related to
PID, diagnosis, treatment, and survival. PID patients who
were seen starting from July 2005 until January 2010 were
included in the data. At the time of analysis, data were
exported to a Statistical Package for the Social Sciences ﬁle
and an analysis was performed. The study was approved by
the ethical and scientiﬁc research committees of the College
of Medicine at SQUH.
RESULTS
Ninety patients were seen during the study period who
received a diagnosis of primary immunodeﬁciency: 55 males
and 35 females, with an estimated prevalence of 4.5 cases
per 100,000. According to the international classiﬁcation of
primary immunodeﬁciency, the most common type of
immunodeﬁciency was phagocytic disorders (42%), followed
by predominantly antibody disorders (18%), other well-
deﬁned PID syndromes (13%), combined immunodeﬁciency
(12%), complement deﬁciencies (6%), unclassiﬁed PID (6%),
and immune dysregulation syndromes (3%) (Fig. 1, Table 1).
In the phagocytic disorders category, the commonest disease
was CGD, representing 31 (82%) of 38 patients with phago-
cytic disorders, making it the commonest PID in Oman (34%
of all PID diseases).
The age of onset of symptoms varied between the ﬁrst
month of life to 12 years of age, with a mean of 20.1 months
and a median of 9 months. The age of diagnosis ranged from
the ﬁrst week of life to 16 years of age, with a mean of 35.5
months and a median of 24 months. Consanguinity was
present in 81% of patients; 10% of patients’ parents were
from the same tribe, and only 9% of patient’s parents were
not related. A family history of PID was present in 42% of the
patients. History of death of a previous child was present in
49% of the patients. The majority of patients (96.6%) showed
pattern of autosomal recessive inheritance, only 3 patients
(3.3%) showed X-linked pattern.
The most common infectious presentation was pneu-
monia; it was present in 42% of cases, followed by deep
abscesses in 27% of patients and then by BCGosis (12%),
chronic diarrhea (10%), superﬁcial abscesses (8%), otitis
media (7%), osteomyelitis (3%), candidiasis (3%), septic
arthritis (1%), and meningitis (1%) (Fig 2).
Other clinical presentations of the study group include
the following: 12% were diagnosed by screening because of
a family history, 8% presented with recurrent nonpruritic
angioedema without urticaria, 6% presented with ataxia, and
7% presented with dysmorphic features. Other features
FIGURE 1. Types of primary immunodeficiency in Oman.
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included failure to thrive, hepatosplenomegaly, lymphade-
nopathy, and skin ulcers. Of the total, 60% required regular
prophylactic antimicrobial therapy, 25% required intravenous
immunoglobulins (IVIG) treatment, 4% required gamma
interferon therapy, and 11% underwent bone marrow trans-
plantation (Fig. 3). A total of 81% of patients are alive and
doing well, 9% are alive but with disabilities related to PID,
and 10% of patients have since died (Fig. 4).
DISCUSSION
The estimated prevalence of PID in Oman is about 4.5
cases per 100,000, which is a higher incidence than the
reported prevalence in European countries.17 The rate of occur-
rence could be even higher because some patients die undiag-
nosed because of a progressive course of infections before
arrival to tertiary care. Additionally, patients with hemophago-
cytic lymphocytic histiocytosis were not included in our regis-
try because they are cared for by the Hematology Unit.
Oman’s PID registry revealed a different pattern of
types of PID as compared with other countries in the region.
In Oman, phagocytic disorders were the most common type.
In this group of PID, CGD represented the most common
disorder, making it the most common form of immunodeﬁ-
ciency in Oman. Curiously, reported registries from different
countries, even in the same region as Oman, identiﬁed anti-
body deﬁciency as the predominant type.8–10 Although we
could assume that PID is underdiagnosed, it would be
unlikely that this is only reﬂected in the diagnosis of certain
types of PID, so the ﬁnding that phagocytic disorder is the
most common type of PID is likely to be true.
There is an overall delay in diagnosis by 15.4 months
from the time of onset of symptoms, although there is less of
a delay when compared with other registries.10 This could be
because many treating physicians do not think of immunode-
ﬁciency as an underlying cause of illness until there have
been many recurrences of infections, which eventually lead
to growth failure, or patients requiring longer stays in hospi-
tal. Pneumonia was the most common infectious presentation
as seen in other registries and was seen in all types of PID. It
was followed by deep abscesses (mainly recurrent lymphad-
enitis), which is a key presentation of CGD.18
Oman has one of the highest immunization coverage
rates in the world,19 and the BCG vaccination is part of the
routine expanded program of immunizations because of
endemic tuberculosis.20 Except when there is a family history
of immunodeﬁciency, the BCG vaccine is given after birth and
before discharge to all newborns in Oman. Eleven patients
TABLE 1. Types of Immunodeficiency, Diagnosis, and
Number of Patients





Common variable immunodeﬁciency, 5
Hyper IgM syndrome, 2





Severe combined immunodeﬁciency, 5






Interferon gamma receptor II deﬁciency, 2
Severe congenital neutropenia, 2
Leukocyte adhesion defect type-1, 1
Pearson syndrome (infections due to
neutropenia), 1
Severe neutrophil defect, granules defect, 1
Complement deﬁciencies,
5 patients
Complement 3 deﬁciency, 1
Complement 7 deﬁciency, 1
C1 Esterase inhibitor deﬁciency type-1, 2
C1 Esterase inhibitor deﬁciency type-2, 1




Cartilage hair hypoplasia, 1
Chronic mucocutaneous candidiasis, 1
Autosomal recessive hyper-IgE
syndrome, 2








4 patients presented with nonpruritic
angioedema without urticaria but C1
esterase inhibitor was normal, and one
patient presented with recurrent infections
but investigations were normal
FIGURE 2. Infectious presentation of PID patients,
percentage values from total number.
FIGURE 3. Treatment of PID patients.
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presented with BCGitis, which is a very difﬁcult infection to
treat in PID patients and associated with great morbidity and
mortality in its disseminated form.21 Oman has been polio free
since 199322; none of our patients presented with polio-related
disease attributed to the vaccine. This could be because of
protective maternal polio IgG passed to infants before delivery.
The inactivated polio vaccine is available for immunodeﬁcient
children and children pending evaluation because of family
history of PID and is now set to replace oral polio vaccine
(OPV) in routine immunizations.
Consanguineous marriages are still customary in
Oman,23 and 81% of our patients were born to consanguine-
ous parents. This number may be higher because some were
from the same tribe but were not consanguineous. This rep-
resents a risk factor not only for PID but all genetic disorders
and, naturally, autosomal recessive immunodeﬁciency disor-
ders are more common in Oman and other Middle Eastern
countries as compared with Western countries. The ﬁnding
that 49% of PID patients have previous infant/child death
makes it an important clinical feature.
All World Health Organization essential drugs are
available in Oman, and treatment of PID is based on the
type and severity of the underlying immunodeﬁciency
disease. Acute infections require antimicrobial drugs that
are readily available in all hospitals. In their usual status, PID
patients may require prophylactic antimicrobial therapy to
prevent recurrent infections and IVIG for antibody and
combined immunodeﬁciencies. The Bone Marrow Transplant
Unit at SQUH has 2 beds, and recently, 2 more beds have
been added. It is the only unit in the country for children and
adult allogeneic stem cell transplant (SCT), which is
performed for hematological malignancy, hemoglobinopathy,
primary immunodeﬁciency, and other inborn errors of
metabolism. Ten patients with PID received stem cell trans-
plants during the study period; all survived except one patient
with severe combined immunodeﬁciency, who came in with
an advanced disseminated stage of BCG-related infection.
The overall mortality rate for all PID patients was 10%,
which is lower than reported rates in similar registries.8,10,11
This could be due to the availability of IVIG and SCT for PID
patients in Oman. Some of the PIDs are incurable by SCT and
are associated with other systems’ involvement, such as neu-
rodegeneration and the development of malignancies, which
contribute to morbidity and mortality. Some of our patients
are alive but have disabilities because of unavoidable com-
plications associated with PID.
CONCLUSIONS
The estimated minimum prevalence of PID in Oman is
4.5 cases per 100,000, higher than that in European countries.
The predominant type is phagocytic disorders, mainly CGD.
The commonest presentation was pneumonia and deep
abscess with median delay of diagnosis of 15.4 months from
onset of symptoms. Consanguinity and presence of previous
infant/child death were signiﬁcant factors. Although the
survival rate is very good, further reduction in the delay of
diagnosis should improve survival rates; this could be done
by increasing the awareness of risk factors and the clinical
presentations of PID among the public and physicians.
Furthermore, development of fully specialized/integrated
immunology units with physicians, nurses, dietitians, social
workers, and proper isolation facilities is essential for patients
to receive a high standard of care. In addition, specialized
immunological laboratory tests should be readily available in
the country to facilitate early diagnosis and management of
PID patients. Resources for genetic research in primary
immunodeﬁciency should be encouraged to identify the
genetic causes of PID in Oman and establish a baseline
genetic information for future customized genetic testing,
gene therapy, and better counseling for families to prevent the
occurrence of PID.
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